Bayer’s Kerendia (finerenone) Receives Health Canada’s Approval for the Treatment of Chronic Kidney Disease and Type 2 Diabetes
Shots:
- Kerendia received approval as an additive to SoC in adults with CKD & T2D to reduce the risk of end-stage kidney disease & sustain reduction GFR, CV death, non-fatal myocardial infarction & hospitalization for heart failure
- The approval was based on the results from the P-III (FIDELIO-DKD) & (FIGARO-DKD) studies evaluating the safety & efficacy of Kerendia +SoC vs PBO on kidney & cardiovascular outcomes of patients (n=13,000) with CKD associated with T2D across 47 countries incl. the US, EU, Japan, China
- Kerendia is a non-steroidal, selective antagonist of the mineralocorticoid receptor that has depicted a blockage of harmful effects of mineralocorticoid receptor overactivation. Additionally, Kerendia has been approved by the US FDA (Jul 2021) & EC (Feb 2022)
Ref: Newswire.Ca | Image: Bayer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
